XR 5118

Drug Profile

XR 5118

Latest Information Update: 29 Jul 2004

Price : $50

At a glance

  • Originator Xenova Group
  • Class Antithrombotics; Piperazines
  • Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 29 Jul 2004 Discontinued - Preclinical for Thrombosis in Netherlands (unspecified route)
  • 29 Jul 2004 Discontinued - Preclinical for Ischaemic heart disorders in Netherlands (unspecified route)
  • 25 Jul 2002 No development reported - Preclinical for Thrombosis in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top